Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1217P (RNA, U6 small nuclear 1217, pseudogene) is a human pseudogene corresponding to U6 small nuclear RNA (snRNA), itself a key non-coding RNA involved in spliceosome function and pre-mRNA splicing[1][3]. Pseudogenes like RNU6-1217P are DNA sequences resembling functional genes but lacking the ability to encode functional RNAs or proteins, usually due to disabling mutations or incomplete sequences[2]. While some pseudogenes can influence gene expression or participate as competitive endogenous RNAs, there is no evidence that RNU6-1217P has any established biological function, disease association, or therapeutic potential. It is not considered a receptor, enzyme, drug target, or biomarker[2]. The entry is considered "incorrect" as a therapeutic target, as pseudogenes are generally not functional targets; rather, they may complicate genetic assays by sequence similarity with functional gene family members[2][5]. If you intended the functional U6 snRNA, that is a critical spliceosomal RNA; however, "RNU6-1217P" specifically denotes a pseudogene (an inactive genetic relic) rather than a functional molecular target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1217, pseudogene (RNU6-1217P).